<DOC>
	<DOCNO>NCT02102646</DOCNO>
	<brief_summary>The purpose study investigate androgen deprivation therapy men prostate cancer increase hepatic fat content change visceral/subcutaneous fat distribution .</brief_summary>
	<brief_title>MRI Substudy ; Metabolic Changes Due Iatrogenic Hypogonadism</brief_title>
	<detailed_description>This substudy ongoing randomize trial entitle : Metabolic Changes Due Iatrogenic Hypogonadism Patients With Prostate Cancer : Orchiectomy vs. Triptorelin ( EudraCT number : 2013-002553-29 ) . 20 consecutive patient anticipated participate regardless assignment either orchiectomy triptorelin .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Eligible inclusion patient include already ongoing Randomised trial entitle : Metabolic Changes Due Iatrogenic Hypogonadism Patients With Prostate Cancer : Orchiectomy vs. Triptorelin ( EudraCT number : 201300255329 ) Implanted device foreign metallic body incompatible Magnetic Resonance Imaging . claustrophobia Severe Psychiatric disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>